参考文献/References:
[1] Miki T,Itoh T,Sunaga D,et al. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning[J]. Cardiovasc Diabetol,2012,11:67.
[2] Elgariah M,El Nasr MA,Fawzy H,et al. Effect of terminal warm reperfusion (hot shot) and remote ischemic preconditioning,either separately or combined,on myocardial recovery in adult cardiac surgery[J]. J Egypt Soc Cardiothorac Surg,2017,25(3):230-235.
[3] Wider J,Undyala VVR,Whittaker P,et al. Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication[J]. Basic Res Cardiol,2018,113(3):16.
[4] Zhang BF,Jiang H,Chen J,et al. Nobiletin ameliorates myocardial ischemia and reperfusion injury by attenuating endoplasmic reticulum stress-associated apoptosis through regulation of the PI3K/AKT signal pathway[J]. Int Immunopharmacol,2019,73:98-107.
[5] 孙凤娟,赵圣刚,江力勤. PI3K/AKT信号通路与心肌缺血再灌注损伤[J]. 中国心血管病研究,2017,15(11):968-972.
[6] Yu X,Shen N,Zhang ML,et al. Egr-1 decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK signal balance in mice[J]. EMBO J, 2011,30(18):3754-3765.
[7] Li J,Xuan W,Yan R,et al. Remote preconditioning provides potent cardioprotection via PI3K/Akt activation and is associated with nuclear accumulation of β-catenin[J]. Clin Sci (Lond),2011,120(10):451-462.
[8] Wu W,Liu X,Han L. Apoptosis of cardiomyocytes in diabetic cardiomyopathy involves overexpression of glycogen synthase kinase-3β[J]. Biosci Rep,2019;39(1):BSR20171307.
[9] Azul L,Leandro A,Boroumand P,et al. Increased inflammation,oxidative stress and a reduction in antioxidant defense enzymes in perivascular adipose tissue contribute to vascular dysfunction in type 2 diabetes[J]. Free Radic Biol Med,2020,146:264-274.
[10] Ghazizadeh Z,Khaloo P,Alemi H,et al. Definition of an oxidative stress status by combined assessment of malondialdehyde and oxidized-LDL:a study in patients with type2 diabetes and control[J]. Meta Gene,2019,19:91-97.
[11] Fangel MV,Nielsen PB,Kristensen JK,et al. Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type 2 diabetes without cardiovascular disease:a Danish cohort study[J]. Am J Med,2020,133(6):e269-e279.
[12] Ling L,Shen Y,Wang K,et al. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus:relevance to impaired endothelial progenitor cells mobilization[J]. PLoS One,2012,7(11):e50739.
[13] 韦勇,杨四军. 细胞自噬的调控与自噬程序性死亡的研究进展[J]. 国际免疫学杂志,2016,39(5):493-497.
[14] Xu X,Kobayashi S,Timm D,et al. Enhanced mTOR complex 1 signaling attenuates diabetic cardiac injury in OVE26 mice[J]. FASEB J,2019,33(11):12800-12811.
[15] Li J,Rohailla S,Gelber N,et al. MicroRNA-144 is a circulating effector of remote ischemic preconditioning[J]. Basic Res Cardiol,2014,109(5):423.
[16] Basalay M,Mastitskaya S,Mrochek A,et al. Reply:glucagon-like peptide-1 mediates cardioprotection by remote ischaemic conditioning[J]. Cardiovasc Res,2017,113(1):13-14.
[17] Tyagi S,Singh N,Virdi JK,et al. Diabetes abolish cardioprotective effects of remote ischemic conditioning:evidences and possible mechanisms[J]. J Physiol Biochem,2019,75(1):19-28.
[18] Cameron AR,Morrison VL,Levin D,et al. Anti-inflammatory effects of metformin irrespective of diabetes status[J]. Circ Res,2016,119(5):652-665.
[19] Ram E,Lavee J,Tenenbaum A,et al. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation[J]. Cardiovasc Diabetol,2019,18(1):118.
相似文献/References:
[1]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(1):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[2]李嘉仪 黄龙祥 罗素新.钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
LI JiayiHUANG LongxiangLUO Suxin.SGLT-2 Inhibitors in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
[3]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(1):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[4]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[5]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(1):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
[6]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(1):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[7]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(1):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[8]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(1):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[9]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(1):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[10]吴易航 张宇辉 张健.SGLT2 i恩格列净对2型糖尿病患者心脏保护作用的研究进展[J].心血管病学进展,2020,(8):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]
WU Yihang,ZHANG Yuhui,ZHANG Jian.Progresses on the Cardiovascular Protection of SGLT2 Inhibitor Empagliflozin in Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(1):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]